Investigation Report on China Moxifloxacin Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||333484|
|出版日期||內容資訊||英文 20 Pages
|Moxifloxacin的中國市場分析 Investigation Report on China Moxifloxacin Market, 2010-2019|
|出版日期: 2015年06月18日||內容資訊: 英文 20 Pages||
Moxifloxacin為第四代奎諾酮類抗菌藥被開發了。1999年自FDA (美國食品藥物管理局) 獲得認證，以「Avelox」的產品名稱上市。中國國內2002年上市。2005年達6000萬人民幣的市場規模，以30.8％年複合成長率(CAGR) 成長，2014年達6億4900萬人民幣。Moxifloxacin為代表性抗菌藥，今後預期市場也將持續成長。
As the fourth generation of quinolones drugs, moxifloxacin (moxifloxacin hodrochloride) was first introduced to the market by The Bayer Group in Sep. 1999. It is utilized in the treatment of adult patients (aged 18 and above) diagnosed with upper and lower respiratory tract infections, e.g. acute sinusitis, acute exacerbation of chronic bronchitis (AECB), community-acquired pneumonia, and skin and soft issue infection.
Moxifloxacin was put in the market in Sep. 1999. Having received the approval of American Food and Drug Administration (FDA) on Dec10, 1999, Moxifloxacin entered the US under the trade name of "Avelox".
In the second half year of 2002, Moxifloxacin was marketed by The Bayer Group and Beijing Bayer Healthcare Co., Ltd in China. Key markets were major hospitals in large and medium-sized cities in China. Moxifloxacin grew at a rapid pace after entering the Chinese market, with its annual sales value rising from less than CNY 60 million in 2005 to CNY 649 million in 2014 andits CAGR from 2005 to 2014 reaching 30.8%. Moxifloxacin is of great demand in China. Currently, moxifloxacin for sale in China are mainly produced by Nanjing Youke Pharmaceutical CO., Ltd and The Bayer Group whichowns the larger market share of over 95% for sales value in 2014.
As an outstanding antibacterial drug, moxifloxacin is granted with a bright future of application. It is estimated that the moxifloxacin market in China will keep growing in the following few years.
Readers can have access to at least the following information through this report:
The author suggests the following groups of people purchase this report: